Keyora Vitex: Clinical Applications and Regulatory Mechanisms in Endocrine Disorders

0009-0007-5798-1996 DOI: 10.17605/OSF.IO/4R856
Description
Wiki

Background

Cognitive fatigue, anxiety, insomnia, PMS/PMDD, and perimenopausal complaints share a common pathophysiology: a coupled breakdown across neurotransmission, endocrine feedback, and cellular energetics.

This work integrates basic, translational, and clinical evidence to position Vitex agnus-castus (Vitex) as a systems-level modulator within a neuro–endocrine–metabolic framework.

Objective

To synthesize the full mechanistic and clinical scope of Vitex - spanning dopaminergic, serotonergic, and GABAergic signaling; HPA/HPG axes; mitochondrial bioenergetics and antioxidant defenses; neurotrophic/synaptic plasticity; objective neurophysiology and sleep architecture; safety; and nutrient synergies - into an actionable model for functional nutritional psychiatry.

Approach

Narrative integration of in vitro, in vivo, neuroimaging, and randomized clinical data across seven domains:

(1) neurotransmission-energy interconnection;

(2) energy substrates and metabolic synergy;

(3) mitochondrial homeostasis/antioxidant defense;

(4) HPA–mitochondrial crosstalk and cortisol regulation;

(5) neurotrophic upregulation and synaptic plasticity;

(6) integrated reconstruction of neuro–energy–hormonal systems;

(7) anxiety/neuro-stress mechanisms and outcomes.

Clinical metrics include PSQI/ISI, HAM-A/POMS, endocrine panels (cortisol, prolactin, progesterone), neurotrophic (BDNF), redox/energetic markers, EEG/PSG, FDG-PET, and fMRI connectivity.

Key mechanistic findings

- Neurotransmission-energy coupling:

Vitex acts as a partial D₂ agonist to reduce prolactin and restore mesocorticolimbic dopaminergic tone (motivation/executive control), enhances 5-HT synthesis and 5-HT₁A sensitivity (affect and circadian stability), and increases GABA_A responsiveness while promoting glutamate → GABA conversion (anti-hyperarousal).

These changes couple to improved mitochondrial ATP supply, minimizing signal-energy mismatches during cognitive load.

- Metabolic optimization:

Through AMPK activation and PGC-1α/SIRT1/TFAM signaling, Vitex increases glucose uptake, β-oxidation, mitochondrial biogenesis, and membrane potential (Δψm), while reducing electron-leak–derived ROS.

Nrf2–ARE induction elevates SOD/GPx/CAT, establishing a sustained antioxidant “enzyme profile” beyond direct radical scavenging.

- HPA–HPG and circadian recalibration:

Upstream D₂ activation dampens CRH–ACTH–cortisol throughput and restores negative feedback sensitivity (GR), re-establishing an inverse cortisol-melatonin rhythm.

Concurrently, reduced prolactin supports luteal function and endogenous progesterone, bridging HPA–HPG cross-talk relevant to PMS/PMDD and perimenopause.

- Neurotrophic and circuit-level repair:

Vitex upregulates BDNF via CREB and potentiates TrkB→PI3K-Akt/MAPK-ERK cascades, increasing synapsin I/PSD-95, dendritic spine density, and LTP.

At the systems level, fMRI indicates strengthened amygdala–prefrontal anti-correlations, aligning emotional control with executive oversight.

Objective outcomes (range across studies/models):

  • decreases in HAM-A (~30%), PSQI/ISI (≈25–32%);
  • normalization of diurnal cortisol (≈20–28% reductions with phase resynchronization) and prolactin;
  • increases in serum 5-HT (~18–25%), GABA (~15–22%), BDNF (~25–45%);
  • EEG alpha↑/beta↓;
  • PSG deep sleep (N3)↑ and REM↑ with fewer awakenings;
  • FDG-PET glucose utilization↑ in PFC/hippocampus;
  • Δψm and ATP↑ with ROS and MDA↓.

Nutrient co-factor synergy

  • Alpha-linolenic acid (ALA) improves membrane fluidity and ETC efficiency;
  • magnesium stabilizes NMDA/GABA_A and Mg-ATP kinetics;
  • zinc supports GAD, SOD, and GR conformational function;
  • vitamin B6 (PLP) accelerates DA/5-HT synthesis.

Together they create a “signal–substrate–structure” loop that amplifies Vitex’s effects (faster recovery of energy metrics, stronger synaptic outputs, and greater anti-stress resilience).

Clinical indications and measurement 

PMS/PMDD, anxiety-related insomnia, perimenopausal mood/sleep disturbance, and stress-linked cognitive fatigue/high workload.

Recommended composite endpoints: PSQI/ISI, HAM-A/POMS, sustained attention/working memory tasks, morning–evening cortisol curve, prolactin / progesterone, and serum BDNF, complemented by EEG/PSG and selective fMRI/FDG-PET where feasible.

Conclusion 

Vitex functions not as a sedative or hormone replacement, but as a neuro–endocrine–metabolic synchronizer: D₂/5-HT/GABA rebalancing, AMPK-driven mitochondrial optimization with Nrf2 antioxidant defense, HPA/HPG and circadian resynchronization, and BDNF-guided synaptic/circuit regeneration.

Implemented alone or with ALA–Mg–Zn–B6, it provides an evidence-aligned, measurable path from symptom relief to homeostatic restoration and neural resilience, advancing the agenda of functional nutritional psychiatry.

Background and Rationale

Functional endocrine disorders such as Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), anovulatory infertility, perimenopausal transition syndromes, stress-related insomnia, and chronic emotional dysregulation often arise from non-organic dysrhythmia of neuro-endocrine feedback loops rather than structural pathology.

Key mechanisms include:

  • Dopaminergic deficiency and hyperprolactinemia, leading to luteal insufficiency and mood instability.
  • Serotonergic and GABAergic imbalance, resulting in sleep–emotion desynchronization.
  • HPA axis hyperactivation, suppressing HPG rhythmicity and reproductive hormones.
  • Neuro-mitochondrial coupling decline, manifesting as cognitive fatigue and stress intolerance.

Vitex agnus-castus offers a unique nutritional-pharmacological route to re-establish these homeostatic loops through functional neuroendocrine modulation rather than exogenous hormone replacement.

The Neuro–Endocrine–Metabolic Tri-Axis Framework

This project defines a unified three-axis model integrating neurotransmitter regulation, hormonal synchronization, and stress-metabolic balance.

Axis I – Neurotransmitter Regulation and Dopaminergic Restoration

Vitex stimulates dopamine D₂ receptors, suppressing pituitary prolactin release.

This shift reverses hyperprolactinemia, enhances luteinizing hormone (LH) secretion, and promotes endogenous progesterone synthesis.

As progesterone stabilizes the central GABAergic tone, mood, emotional stability, and premenstrual irritability markedly improve.

Axis II – Hormonal and Reproductive Homeostasis

Through restoration of the HPG axis feedback loop, Vitex normalizes the estrogen–progesterone ratio and supports regular ovulatory cycles.

This modulation strengthens the endocrine resilience of women experiencing PMS, PMDD, infertility, or perimenopausal transition, achieving steady luteal function without exogenous hormone replacement.

Axis III – Stress–Sleep–Metabolic Integration

By down-regulating HPA overactivity, Vitex lowers excessive cortisol output, mitigates stress-related hormonal suppression, and enhances melatonin synthesis.

Its secondary modulation of 5-HT and GABA signaling improves sleep initiation and continuity, while activation of BDNF and mitochondrial biogenesis pathways restores neuronal energy and cognitive stability under chronic stress.

Mechanism-Specific Disease Contexts

Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Disorder (PMDD)

In PMS and PMDD, the primary defect lies in dopaminergic insufficiency and consequent prolactin elevation.

Vitex acts on the D₂ receptor to suppress prolactin, thereby elevating luteal progesterone and alleviating cyclic mood swings, tension, and breast tenderness.

Clinical trials demonstrate that this dopaminergic correction directly improves both somatic and emotional PMS symptoms.

Perimenopausal Hormonal Transition

During perimenopause, fluctuating estrogen and progesterone levels activate the HPA axis, amplifying anxiety and vasomotor instability.

Vitex re-establishes HPG rhythmicity while suppressing cortisol hypersecretion, leading to significant improvements in anxiety, sleep quality, and thermoregulatory symptoms.

Stress-Related Insomnia and Emotional Dysregulation

Chronic stress leads to excessive cortisol and suppressed GABAergic inhibition, resulting in insomnia and agitation.

Vitex increases serotonin turnover and enhances GABA receptor activity, simultaneously stimulating melatonin pathways.

These combined effects produce relaxation, shorten sleep latency, and restore circadian coherence.

Neuro-Cognitive Fatigue and Mitochondrial Dysfunction

Sustained stress reduces neuronal energy and BDNF signaling.

Vitex activates Nrf2, SIRT1, and PGC-1α transcriptional networks, enhancing mitochondrial biogenesis and synaptic resilience.

This underlies its role in cognitive recovery and sustained attention performance under high mental workload.

Mechanistic Integration – From Signal Correction to Systemic Homeostasis

The regulatory actions of Vitex agnus-castus operate sequentially yet interdependently.

Activation of dopamine D₂ receptors suppresses prolactin, enabling progesterone synthesis that feeds back to stabilize both HPG and HPA activity.

Simultaneously, normalization of serotonin and GABA signaling re-entrains the sleep–emotion–endocrine rhythm, while mitochondrial and neurotrophic pathways (BDNF, PGC-1α, TFAM) restore neuronal energetics.

Together, these cascades establish a closed regulatory circuit that transitions the body from symptom control to functional homeostasis - the essence of FNEM.

Clinical and Translational Evidence

A growing body of clinical research confirms the translational validity of these mechanisms.

Randomized controlled trials such as Schellenberg et al. (2012, Phytomedicine) and Atmaca et al. (2014, Journal of Women’s Health) demonstrated that Vitex extract significantly reduced anxiety, mood swings, and sleep disturbance in PMS populations while lowering prolactin and increasing progesterone levels.

Hidalgo et al. (2017, Gynecological Endocrinology) further validated its capacity to decrease cortisol and anxiety in perimenopausal women, confirming its bidirectional HPA–HPG modulation.

Preclinical evidence from Wuttke and Jarry (2003, Phytomedicine) established the dopaminergic principle through in-vitro D₂ activation.

Collectively, these findings consolidate Vitex as a mechanistically coherent and clinically translatable FNEM.

Methodology and Open-Science Principles

This project integrates molecular, physiological, and clinical layers through an open, evidence-based synthesis.

Searches encompass PubMed, Embase, Cochrane Library, and Web of Science using standardized keywords (Vitex agnus-castus, dopamine D₂, prolactin, progesterone, HPG, HPA, 5-HT, GABA, BDNF, sleep, perimenopause).

Data extraction follows PRISMA-ScR guidelines; bias assessment employs RoB 2, and evidence grading follows the GRADE framework.

All extracted data, diagrams, and analysis scripts are archived within the OSF project components to ensure transparency and reproducibility.

Clinical Relevance and Population Scope

The translational goal of this project extends beyond hormonal regulation toward restoring system-level equilibrium.

Applicable populations include women experiencing PMS or PMDD, perimenopausal transition, infertility due to luteal insufficiency, stress-related insomnia, and chronic fatigue with emotional dysregulation.

These conditions share a common neuro-endocrine disconnection pattern, and Vitex provides a physiologically adaptive means to restore intrinsic hormonal and neurochemical plasticity.